"In the clinic, I think the biggest benefit, at least immediately, is that by asking and trying to figure out what a patient's tobacco use history is, you can help with quitting,” says Richard Matulewicz, MD, MS.
In this video, Richard Matulewicz, MD, MS, discusses the takeaways of the study, “Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials,” presented recently at the 2021 American Urological Association Annual Meeting. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.